Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06234631 · ClinicalTrials.gov registry record · Phase 2

Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty

A Phase 2 study of Osteoarthritis, Knee and Knee Replacement Surgery, sponsored by Chad Brummett.

Recruiting
Registry status
Phase 2
Development phase
380
Enrollment target
2
Study locations

NCT06234631: Recruiting Phase 2 study of Osteoarthritis, Knee and Knee Replacement Surgery, sponsored by Chad Brummett.

NCT06234631 is a Phase 2 study of Osteoarthritis, Knee and Knee Replacement Surgery that is actively recruiting participants, run by Chad Brummett. The registered enrollment target is 380 participants, below the 494-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (23% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06234631, a Phase 2 study of Osteoarthritis, Knee and Knee Replacement Surgery, is actively recruiting participants, sponsored by Chad Brummett.

RECRUITING
Registry status
Phase 2
Development phase
380 participants
Enrollment target
2
Study locations

Study Summary

The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whether CBD may be a useful medication before and/or after surgery. The study hypothesis is that CBD exerts opioid-sparing effects through anti-inflammatory, analgesic, and anxiolytic mechanisms.

Interventions

  • OTHER Placebo
  • DRUG Epidiolex oral solution

Study Locations (2)

Michigan

  • University of Michigan - Ann Arbor
  • Henry Ford Health System - Detroit

Trial Details

FieldValue
Enrollment Target 380 participants
Start Date 2024-03-13
Est. Completion 2029-01
Phase Phase 2
Chad Brummett

1 total trials

What NCT06234631 shows while recruiting

NCT06234631 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, below the 494-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (23% lower).

The record links to 2 conditions, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06234631 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT06234631 about?

NCT06234631 is a clinical study titled "Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty". The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whe...

What is the current status of trial NCT06234631?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2024-03-13. Estimated completion is 2029-01.

What conditions does trial NCT06234631 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee, Knee Replacement Surgery.

What interventions are being tested in trial NCT06234631?

The interventions under investigation include: Placebo (OTHER), Epidiolex oral solution (DRUG).

Who is sponsoring clinical trial NCT06234631?

This trial is sponsored by Chad Brummett, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06234631 being conducted?

This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06234631's enrollment target sits among peer trials

380 22nd of 112 higher than 90 of 112 other Osteoarthritis, Knee trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoarthritis, Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04560673 · 380 participants · Phase 2

    Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

  • NCT04777357 · 380 participants · Phase 3

    A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

  • NCT04821154 · 380 participants

    Persona Revision Knee System Outcomes

  • NCT05102019 · 380 participants · NA

    Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06234631, the US trial registry maintained by the National Library of Medicine. NCT06234631 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.